Needham Maintains Buy on Recursion Pharmaceuticals, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and raises the price target from $15 to $17.
February 28, 2024 | 10:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum reaffirms a Buy rating on Recursion Pharmaceuticals and increases the price target from $15 to $17.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100